Biocon: Enhancing Global Healthcare

Biocon Limited is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe.

An innovation-led organization focused on providing affordable access, Biocon has built differentiated capabilities in the areas of biologics and complex small molecules. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'.

Biocon’s key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, Insugen®; insulin analog Glargine, Basalog®; India’s first indigenously produced monoclonal antibody, BIOMAb-EGFR®; the world’s first humanized anti-CD6 monoclonal antibody, Itolizumab, launched as ALZUMAb™ in India; CANMAb™, the first follow-on biologic Trastuzumab to be approved anywhere in the world.

The company’s aspiration to become a US$1 billion company by FY19 is fuelled by four powerful growth accelerators: Small Molecules, Biologics, Branded Formulations and Research Services, represented by its subsidiary Syngene. The Small Molecules vertical offers a strong portfolio of differentiated APIs across statins, immunosuppressants, specialty molecules as well as difficult-to-make, niche Generic Formulations. The Biologics vertical comprises novel biologics and biosimilars, including rh-insulin, insulin analogs, monoclonal antibodies and recombinant proteins. The Branded Formulations business includes the company’s finished dosages business in India and overseas including UAE. Syngene is Asia’s largest contract research and manufacturing organization.